Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

This pilot trial (n=101) found those randomised to inhaled nebulised interferon beta-1a for 14 days had greater odds of improvement in clinical condition during the dosing phase, as measured by the WHO Ordinal Scale for Clinical Improvement (OR 2.32; 95% CI 1.07-5.04; p=0.033).

SPS commentary:

The authors say the findings of their study provide a rationale for larger, international studies in the context of the ongoing clinical burden of Covid-19.

The Lancet Respiratory Medicine